Skip to main content
. Author manuscript; available in PMC: 2018 Jun 5.
Published in final edited form as: Integr Biol (Camb). 2018 Feb 16;10(3):145–158. doi: 10.1039/c7ib00179g

Fig. 1.

Fig. 1

CD44v6 alters tumor growth and architecture in vivo. (A) Schematic showing the establishment of a gastric cancer (GC) cell line stably expressing CD44v6 and study design for subcutaneous xenograft injections of GC cells individually in SCID mice. (B) Immunofluorescence images showing CD44v6 isoform expression and nuclei (DAPI) on MKN74 and CD44v6 cells. Scale bars = 50 μm. Inset bars = 20 μm. (C) Representative histograms of MKN74 and CD44v6 analysis by flow cytometry quantifying CD44v6 expression. (D) Tumor volume from MKN74 (n = 3) and CD44v6 (n = 8) subcutaneous xenografts over eight weeks of growth and representative gross images of explanted tumors at week 8. Scale bars = 5 mm. (E) Histological grading and representative photomicrographs of the desmoplastic response of MKN74 and CD44v6 subcutaneous xenografts on Hematoxylin and Eosin (H&E) stained sections with confirmation of collagen deposition (blue) via Masson’s Trichrome-stained sections after 8 weeks of subcutaneous injection. Arrows indicate fibrotic tissue. Scale bars = 25 μm, inset bars = 50 μm.